Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
5.45 ^USD	-0.37%		-7.94%	-3.54%

Mar. 14	Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline	MT
Mar. 14	Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2022

August 11, 2022 at 07:30 am EDT

Monte Rosa Therapeutics, Inc. reported earnings results for the second quarter ended June 30, 2022. For the second quarter, the company reported net loss was USD 26.47 million compared to USD 18.41 million a year ago. Basic loss per share from continuing operations was USD 0.57 compared to USD 3.63 a year ago.

Latest news about Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Q4 Net Loss Narrows; Shares Decline	Mar. 14	MT
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 14	CI
Monte Rosa Therapeutics, Inc. Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1b Pathway Inhibitor	Mar. 11	CI
Wedbush Starts Monte Rosa Therapeutics With Outperform Rating, $11 Price Target	Feb. 15	MT
Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Monte Rosa Therapeutics Partners With Roche in Targeting Cancer, Neurological Diseases; Shares Surge Pre-Bell	23-10-17	MT
Transcript : Monte Rosa Therapeutics, Inc. - Special Call	23-10-17
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors	23-10-17	CI
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases	23-10-17	CI
Monte Rosa Says on Track to File Application for Autoimmune Diseases Treatment, Provide Initial Data on Solid Tumors Therapy	23-08-10	MT
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Monte Rosa Therapeutics, Inc. Appoints Anthony M. Manning to the Board of Directors	23-07-26	CI
Monte Rosa Therapeutics Advances Second Development Candidate	23-05-23	MT
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, A Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases	23-05-23	CI
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Monte Rosa Therapeutics, Inc. Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023	23-04-17	CI
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors	23-03-23	CI
Credit Suisse Trims Monte Rosa Therapeutics' Price Target to $11 From $12, Keeps Neutral Rating	23-03-17	MT
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-16	CI
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-03-16	CI
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Price Target at $18	23-01-03	MT
Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2022	22-11-10	CI
Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359	22-11-01	CI
UBS Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $22 Price Target	22-10-13	MT

Chart Monte Rosa Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs) for patients living with serious diseases in the areas of oncology and autoimmune, and more. MGDs are small molecule drugs that employ the bodyâs natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a degradation platform, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.45 USD

Average target price

15.71 USD

Spread / Average Target

+188.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MONTE ROSA THERAPEUTICS, INC.	-3.54%	274M
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B

Other Biotechnology & Medical Research